Jun 22, 2022 5:50pm EDT Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)
Feb 14, 2022 8:00am EST Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures
Feb 09, 2022 6:30pm EST Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021